This site is intended for healthcare professionals outside the US.

After VEGFR-TKI failure in aRCC,

AFINITOR more than doubled median PFS as compared with placebo1

After VEGFR-TKI failure in aRCC, AFINITOR more than doubled median PFS: As shown in RECORD-1 PFS in patients treated with 1 or 2 prior VEGFR-TKIs.

As shown in a post-hoc subanalysis of RECORD-1,
AFINITOR demonstrated efficacy after either 1 or 2 VEGFR-TKIs2

In a post-hoc subanalysis of RECORD-1, median PFS with AFINITOR was 5.4 months after 1 VEGFR-TKI and 4.0 months after 2 VEGFR-TKIs

*Median PFS in patients who received 1 or 2 prior VEGFR-TKIs, evaluated by Independent Central Review Board.2
Median PFS in patients who received only 1 prior VEGFR-TKI and median PFS in patients who received 2 prior VEGFR-TKIs by treatment arm in a post-hoc subanalysis of RECORD-1. These data are not a part of the AFINITOR Summary of Product Characteristics.1
Abbreviations:
aRCC, advanced renal cell carcinoma; PFS, progression-free survival; VEGFR-TKI, vascular endothelial growth factor receptor-tyrosine kinase inhibitor.
References:
  1. AFINITOR [summary of product characteristics]. Novartis Pharma AG; 2016.
  2. Calvo E, Escudier B, Motzer RJ, et al. Everolimus in metastatic renal cell carcinoma: subgroup analysis of patients with 1 or 2 previous vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapies enrolled in the phase III RECORD-1 study. Eur J Cancer. 2012;48(3):333-339.